Abstract 396P
Background
Despite the many cervical cancer prevention interventions recommended and supported by WHO and partners of low- and middle-income countries; the burden of cancer is high in Uganda and the East African region. Little is known about factors associated with participating in screening at a primary health facility (PHF) and referral to a high-level facility.
Methods
A cross-sectional study was conducted from February to March 2018 at Uganda Cancer Institute (UCI) among women visiting for cervical cancer screening. A structured questionnaire was used. Women suspected for cervical cancer and provided consent were enrolled and administered the questionnaire. Ethics review and approval was obtained from UCI research and ethics committee. A Stata version 14.1 software was used and Chi-square tests and multivariate logistic regression analyses performed.
Results
Among 522 women enrolled, only 3.26% (17) had a formal referral note and 62.64% (327) had participated in cervical cancer screening before visiting UCI. There was a 17.65% false-positive rate among the referred women suspected with cervical cancer. 67.18% (131) among those who had never screened reported personal beliefs as a factor deterring their participation. Most women were aged between 35-44 years old (ORs=2.45, 95% CI = 1.61-3.72) who were divorced/widowed (ORs=1.89, 95% CI = 1.07-3.34) and drinking alcohol (ORs=0.51, 95% CI = 0.31-0.83). Among the referred women, 17.65% delayed to honour a referral request for more than a month because of socio-economic challenges. Factors such as high education level (ORs=0.11, 95% CI = 0.02-0.48) and confirmatory tests (ORs=6.10, 95% CI = 1.93-19.31) done at UCI were associated with referrals.
Conclusions
The present study identified factors associated with participation in screening at a PHF and referral to a high-level facility, which provides better understanding of lost follow-up after screening. Awareness in high risk groups, increase of screening facilities and integration of screening services with existing health programs is necessary.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Uganda Cancer Institute-African Development Bank capacity building fund.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
27P - The prognostic value of neutrophil to lymphocyte ratio (NLR) and 18F-FDG PET SUV in breast cancer patients underwent neoadjuvant chemotherapy
Presenter: Soong June Bae
Session: Poster display session
Resources:
Abstract
28P - Accuracy of core biopsy in predicting pathologic complete response in the breast in patients with complete/near complete clinical and radiological response (Complete Responders in the Breast – CRBr): A feasibility study
Presenter: Nisha Hariharan
Session: Poster display session
Resources:
Abstract
29P - Tumour response to neoadjuvant chemotherapy in breast cancer: Routine pathologic markers improve the predictive power of a cell-loss metric based on release of thymidine kinase 1 into blood
Presenter: Bernhard Tribukait
Session: Poster display session
Resources:
Abstract
30P - Comparison of metabolic changes between neoadjuvant chemotherapy and neoadjuvant endocrine therapy in premenopausal women with ER positive, HER2 negative breast cancer
Presenter: Ho-hyun Ryu
Session: Poster display session
Resources:
Abstract
31P - Circulating miR-155 as a potential therapeutic monitoring marker in breast cancer
Presenter: Sumadi Lukman Anwar
Session: Poster display session
Resources:
Abstract
32P - Profile of breast cancer epidemiology in Sanglah General Hospital, Denpasar, Bali from 2012 to 2019
Presenter: Citra Aryanti
Session: Poster display session
Resources:
Abstract
33P - Contrast enhanced chest CT in patients with breast cancer: Comprehensive imaging analysis and correlation with biological markers
Presenter: Bo Hwa Choi
Session: Poster display session
Resources:
Abstract
34P - Verification of metabolic regulatory mechanisms in androgen receptor-positive triple negative breast cancer
Presenter: Yuka Asano
Session: Poster display session
Resources:
Abstract
35TiP - Ribociclib plus goserelin with hormonal therapy versus physician choice chemotherapy in pre-/perimenopausal patients with HR+, HER2– inoperable locally advanced breast cancer (ABC): RIGHT choice study
Presenter: Yen-Shen Lu
Session: Poster display session
Resources:
Abstract
36TiP - A prospective study to assess response to neoadjuvant hormonal therapy in postmenopausal women with hormone-receptor positive breast cancer at a regional cancer centre in South India
Presenter: Shina Goyal
Session: Poster display session
Resources:
Abstract